Hikma jumps 10% as brokers point to profit beat and undemanding rating

Hikma Pharmaceuticals’ shares jumped 10% to 1,721p after first-half results came in ahead of expectations on profits. The upside reaction suggests investors viewed the earnings print as a clear beat versus forecasts, supporting a near-term positive repricing of the stock.

Analysis

Hikma Pharmaceuticals’ shares jumped 10% to 1,721p after first-half results came in ahead of expectations on profits. The upside reaction suggests investors viewed the earnings print as a clear beat versus forecasts, supporting a near-term positive repricing of the stock.